In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for ...

Astellas and Pfizer announced that neoadjuvant plus adjuvant enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

The tickets could go to the lipid-lowering pill enlicitide decanoate and the antibody-drug conjugate sacituzumab tirumotecan, though a spokesperson for the HHS did not confirm the news.

The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker “DCOY” effective in ...

Merck's oral PCSK inhibitor for cholesterol, enlicitide, and its cancer antibody-drug conjugate sacituzumab tirumotecan ...

A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...

Limited (“ HUTCHMED ”) (Nasdaq/AIM:?HCM; HKEX:?13) today announces the initiation of its global Phase I clinical development program for HMPL-A251, a first-in-class PI3K/PIKK-HER2 Antibody-Targeted ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Earnings call Crinetics reported Q3 2025 results with no Palsanafy revenue due to timing of approval but confirmed product shipments began in Q4. R&D and SG&A expenses rose sequentially due to launch ...

GAAP EPS loss narrowed to ($0.40) per share in Q2 2025, and improving from ($0.46) per share (GAAP) in Q2 2024. Further clinical milestones achieved for core oncology drug candidates, with standout ...

AUSTIN, Texas, July 16, 2025 (GLOBE NEWSWIRE) -- via IBN -- Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® ...